Two great aesthetic powers have merged.
The world leader in the pharmaceutical industry Allergan PLC has announced its intention to acquire Kythera Biopharmaceuticals, Inc., known for its aesthetic products.
Allergan, the company in charge of fillers and injectables such as Botox, Juvéderm and Latisse, would have bought the company for $ 2.1 billion.
Recently, Kythera made news with the announcement of her new treatment, Kybella , which offers patients non-surgical treatment for sub-mental fullness (double chin).
“As a leader in esthetics, we know that our clients seek to offer their patients new options beyond traditional facial aesthetics.
Kybella will achieve this while complementing our market-leading facial aesthetic portfolio, “said Brent Saunders, CEO and president of Allergan.
